The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

(RTTNews) - Merck & Co Inc. (MRK), Thursday said it has decided to stop the Phase 3 HYPERION study evaluating Winrevair in pulmonary arterial hypertension (PAH). The HYPERION study is designed to ...

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...